OVERVIEW

As healthcare systems evolve, Pharmacoeconomics will remain a key discipline for guiding decisions that optimize outcomes, resource allocation, and the overall sustainability of healthcare.
The MEPDPS 2025: Middle East Pharmacoeconomics and Drug Policy Summit 2025 will take place on 21-22 February at JW Marriott Hotel Marina, Dubai, UAE and has been meticulously crafted to serve as a dynamic platform for thought leaders, policymakers, and key stakeholders to exchange insights, share experiences, in the areas focused on healthcare policy, the HEOR in healthcare decision making, economic evaluations, VBHC, the implications of HTA, responses to Real-World Evidence, collaboration, affordability, and equity in healthcare, that enhance patient outcomes, ensure accessibility to innovative therapies, and contribute to the sustainability of our healthcare infrastructure.

KEY BENEFITS OF ATTENDING

• Highlight future opportunities and challenges in developing the healthcare and research economy in the GCC countries
• Discuss the novel approaches to value assessment, achieving cost effective healthcare solutions and access to innovative medicines in the GCC
• Understanding the principles of outcome based healthcare and evidence based medication
• Reviewing pharmacoeconomics and outcomes research strategies
• Exploring the real world data, the burden of disease and HTA to make proper assessments and support decision making

THANKS TO OUR PREVIOUS SPONSORS

Gold Sponsors

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Silver Sponsors

SUPPORTER